New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 23, 2013
16:02 EDTIMUCImmunoCellular says first patient in phase I trial of ICT-121 receives vaccine
ImmunoCellular Therapeutics announced that the first patient in the phase I clinical trial of ICT-121, a cancer vaccine targeting recurrent glioblastoma multiforme, has received the vaccine. ICT-121 is a dendritic cell vaccine targeting CD-133, an important cancer stem cell marker that is commonly expressed on a broad range of solid tumors. The company said, “The start of this ICT-121 trial signifies an expansion of our commitment to developing treatments for patients with GBM, and to the continued advancement of our pipeline of dendritic cell-based immunotherapeutic cancer vaccines. In 2014 we expect to have three active cancer vaccine clinical programs, led by ICT-107 in newly diagnosed GBM and including ICT-140 in ovarian cancer and ICT-121.”
News For IMUC From The Last 14 Days
Check below for free stories on IMUC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
08:19 EDTIMUCLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use